Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Alfuzosin Hydrochloride

FDA-approved product (tablet, extended release, oral), marketed as Alfuzosin Hydrochloride, Uroxatral.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Alfuzosin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Benign prostatic hyperplasia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Alpha-adrenoreceptor antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis41.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Alfuzosin Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Alfuzosin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients

    NCT00696761 · start 2006-05

    Registered record
    Registry ID
    NCT00696761
    Conditions
    BPH
    Interventions
    Alfuzosin; Alfuzosin; Alfuzosin; Alfuzosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-05
    Completion
    2008-08
    Enrolment
    232

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBPH
    InterventionAlfuzosin; Alfuzosin; Alfuzosin; Alfuzosin
    PhasePhase 4
    Registry statusCompleted

  • SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin

    NCT00486785 · start 2006-04

    Registered record
    Registry ID
    NCT00486785
    Conditions
    Prostatic Hyperplasia
    Interventions
    Alfuzosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2006-04
    Completion
    2008-03
    Enrolment
    431

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    InterventionAlfuzosin
    PhasePhase 4
    Registry statusCompleted

  • Alfuzosin for Treating Acute Urinary Retention

    NCT00336921 · start 2006-02

    Registered record
    Registry ID
    NCT00336921
    Conditions
    Acute Urinary Retention
    Interventions
    Alfuzosin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-02
    Completion
    Not recorded
    Enrolment
    156

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Urinary Retention
    InterventionAlfuzosin; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Evaluation of Symptom-specific Goal Achievement

    NCT00836823 · start 2005-12

    Registered record
    Registry ID
    NCT00836823
    Conditions
    Benign Prostatic Hyperplasia; Lower Urinary Tract Symptoms
    Interventions
    Alfuzosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-12
    Completion
    2008-08
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia; Lower Urinary Tract Symptoms
    InterventionAlfuzosin
    PhasePhase 4
    Registry statusCompleted

  • Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers

    NCT02266537 · start 2005-11

    Registered record
    Registry ID
    NCT02266537
    Conditions
    Healthy
    Interventions
    Tamsulosin; Alfuzosin; Doxazosin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-11
    Completion
    Not recorded
    Enrolment
    97

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTamsulosin; Alfuzosin; Doxazosin; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Randomized Trial Comparing Alfuzosin GITS 10 mg Daily With Placebo for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up

    NCT00563654 · start 2005-10

    Registered record
    Registry ID
    NCT00563654
    Conditions
    Prostatic Hyperplasia; Urinary Retention; Acute Disease
    Interventions
    Alfuzosin GITS (Xatral XL)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2005-10
    Completion
    2006-11
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia; Urinary Retention; Acute Disease
    InterventionAlfuzosin GITS (Xatral XL)
    PhaseNot applicable
    Registry statusTerminated

  • Alfuzosin Hydrochloride to Promote Passage of Distal Ureteral Calculi

    NCT00177086 · start 2005-09

    Registered record
    Registry ID
    NCT00177086
    Conditions
    Kidney Calculi; Ureteral Calculi; Colic
    Interventions
    Alfuzosin Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-09
    Completion
    2008-01
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Calculi; Ureteral Calculi; Colic
    InterventionAlfuzosin Hydrochloride
    PhasePhase 3
    Registry statusCompleted

  • ALF-ONE : ALFuzosin ONcE Daily

    NCT00280605 · start 2005-08

    Registered record
    Registry ID
    NCT00280605
    Conditions
    Prostatic Hyperplasia
    Interventions
    Alfuzosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-08
    Completion
    2006-02
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    InterventionAlfuzosin
    PhasePhase 4
    Registry statusCompleted

  • Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome

    NCT00103402 · start 2005-02

    Registered record
    Registry ID
    NCT00103402
    Conditions
    Prostatitis
    Interventions
    Alfuzosin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-02
    Completion
    2008-01
    Enrolment
    272

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatitis
    InterventionAlfuzosin; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Dose Ranging Study of Alfuzosin in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia

    NCT00409357 · start 2004-11

    Registered record
    Registry ID
    NCT00409357
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    SL77.0499-10 (alfuzosin hydrochloride)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-11
    Completion
    2005-08
    Enrolment
    473

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    InterventionSL77.0499-10 (alfuzosin hydrochloride)
    PhasePhase 2
    Registry statusCompleted

  • Alfuzosin Versus Placebo in Acute Urinary Retention

    NCT00453908 · start 2004-05

    Registered record
    Registry ID
    NCT00453908
    Conditions
    Urinary Retention
    Interventions
    Alfuzosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2004-05
    Completion
    Not recorded
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrinary Retention
    InterventionAlfuzosin
    PhasePhase 3
    Registry statusTerminated

  • Minimally Invasive Surgical Therapy for BPH

    NCT00064649 · start 2004-04

    Registered record
    Registry ID
    NCT00064649
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    Transurethral Microwave Thermotherapy (TUMT); Transurethral Needle Ablation (TUNA) Therapy; Finasteride and Alfuzosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2004-04
    Completion
    2006-06
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    InterventionTransurethral Microwave Thermotherapy (TUMT); Transurethral Needle Ablation (TUNA) Therapy; Finasteride and Alfuzosin
    PhasePhase 3
    Registry statusTerminated

  • Multicenter Prospective Study on the Changes of Sexual Function Following Treatment With Alfuzosin (Xatral XL®) in Patients With Benign Prostate Hypertrophy

    NCT00542165 · start 2004-03

    Registered record
    Registry ID
    NCT00542165
    Conditions
    BPH/LUTS/Sexual Functions
    Interventions
    Alfuzosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-03
    Completion
    2004-12
    Enrolment
    166

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBPH/LUTS/Sexual Functions
    InterventionAlfuzosin
    PhasePhase 4
    Registry statusCompleted

  • Once Daily Given Alfuzosin in the Treatment of BPH

    NCT00637715 · start 2003-10

    Registered record
    Registry ID
    NCT00637715
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    Alfuzosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-10
    Completion
    2004-12
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    InterventionAlfuzosin
    PhasePhase 4
    Registry statusCompleted

  • Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study

    NCT00575913 · start 2003-09

    Registered record
    Registry ID
    NCT00575913
    Conditions
    Prostatic Diseases
    Interventions
    Alfuzosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-09
    Completion
    2005-03
    Enrolment
    118

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Diseases
    InterventionAlfuzosin
    PhasePhase 4
    Registry statusCompleted